An Open Trial of Allopurinol in Patients With Poorly Responsive Schizophrenia

Bronx Psychiatric Center10 enrolled

Overview

This is a four week open label trial of ALLOPURINOL to the treatment regime of ten (10) poorly responsive patients with schizophrenia, monitoring their response and side-effects. No change in medication is required.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Schizophrenia

Interventions

AllopurinalDRUG

300mg once daily by mouth for four weeks

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Subjects with schizophrenia and poor response (no prospect of discharge because of symptoms) Exclusion Criteria: * Over 65 * Renal or liver disease * Diabetes * Hypertension * Taking thiazides or ACE inhibitors

Outcomes

Primary Outcomes

Change in Positive and Negative Syndrome Scale (PANSS) Measures Symptoms of Schizophrenia

Symptom scale Score 30 (best, no symptoms of schizophrenia) to 210 (worst)

Time frame: baseline and 4 weeks

Secondary Outcomes

Simpson Angus Scale for Parkinsonism

Measures drug induced parkinsonism, score 0 (best, no Parkinsonism) to 36 (worst)

Time frame: baseline and 4 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.